{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"7.0","upperLimit":"14.6","value":"11.3"},{"groupId":"OG001","lowerLimit":"5.7","upperLimit":"11.8","value":"8.6"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"218"},{"groupId":"OG001","value":"107"}],"units":"Participants"}],"description":"TTP is defined as the time from the date of randomization until the earliest date of documented PD (per IMWG Response Criteria) or death due to PD. PD: increase of \\>=25% from lowest confirmed value in any 1 of following criteria: serum M-protein (absolute increase must be \\>=0.5 g/dL), serum M-protein increase \\>=1g/dL if lowest M component was \\>=5g/dL; urine M-component (absolute increase must be \\>=200mg/24 hour),appearance of new lesion(s), \\>=50% increase from nadir in Sum of the Products of the maximal perpendicular Diameters of measured lesions (SPD) of \\>1 lesion, or \\>=50% increase in the longest diameter of previous lesion \\>1 cm in short axis.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants with relapsed/refractory multiple myeloma (RRMM) received 30 minutes intravenous infusion of 2.5 milligram/kilogram (mg/kg) belantamab mafodotin on day 1 of each 21-day cycle","id":"OG000","title":"Belantamab Mafodotin"},{"description":"Participants with RRMM received 4 mg pomalidomide capsule daily on Days 1 to 21 of each 28-day cycle, along with 40 mg or at lower 20 mg (for participants \\>75 years of age) dose of dexamethasone tablet once weekly (Days 1, 8, 15 and 22)","id":"OG001","title":"Pomalidomide Plus Dexamethasone"}],"paramType":"MEDIAN","populationDescription":"ITT Population","reportingStatus":"POSTED","timeFrame":"Up to approximately 263 weeks","title":"Time to Progression (TTP)","type":"SECONDARY","unitOfMeasure":"Months"}